Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsMEPDF 81 Intrinsic Value: Projected FCF is $27.04 as of Aug. 10, 2026, which is 3708% above its 10-year median of 0.71. GuruFocus rates MEPDF with a GF Score™ of 81/100 and a GF Value™ of $17.73. The stock has 3 warning signs investors should review. Among 75 Medical Distribution companies, Medipal Holdings ranks better than 64% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-10), Medipal Holdings's Intrinsic Value: Projected FCF is $27.04. The stock price of Medipal Holdings is $18.35. Therefore, Medipal Holdings's Price-to-Intrinsic-Value-Projected-FCF of today is 0.7.
The historical rank and industry rank for Medipal Holdings's Intrinsic Value: Projected FCF or its related term are showing as below:
MEPDF'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.56 Med: 0.71 Max: 1.02
Current: 0.68
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Medipal Holdings was 1.02. The lowest was 0.56. And the median was 0.71.
MEPDF's Price-to-Projected-FCF is ranked better than 64% of 75
companies
in the Medical Distribution industry
Industry Median: 0.81
vs MEPDF: 0.68
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Medipal Holdings's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
18.35
/
26.963916693676
=
0.68
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medipal Holdings Intrinsic Value: Projected FCF Related Terms
Medipal Holdings Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEPDF vs MCK, COR, CAH: Intrinsic Value: Projected FCF Comparison
For the Medical Distribution subindustry, Medipal Holdings's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings Price-to-Projected-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $27.04 mean?
Medipal Holdings (MEPDF) has a Intrinsic Value: Projected FCF of $27.04 as of Aug. 10, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Medipal Holdings and its competitors. This is 3708% above median its historical median of 0.71. Over the past decade, Medipal Holdings' Intrinsic Value: Projected FCF has ranged from 0.56 to 1.02. According to the industry distribution chart, Medipal Holdings ranks #27 out of 75 companies in the Medical Distribution industry, placing it in the top 36%.
Is Medipal Holdings' Intrinsic Value: Projected FCF too high?
Medipal Holdings' current Intrinsic Value: Projected FCF of $27.04 is 3708% above median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 1.02. The Medical Distribution industry median Intrinsic Value: Projected FCF is 0.81. Medipal Holdings' value of $27.04 is 3238.3% above this industry median. Based on the distribution chart, Medipal Holdings ranks #27 out of 75 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Intrinsic Value: Projected FCF compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #27 out of 75 companies for Intrinsic Value: Projected FCF. This puts Medipal Holdings in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 0.81. Medipal Holdings' value of $27.04 is 3238.3% above this benchmark. Historically, Medipal Holdings' own Intrinsic Value: Projected FCF has ranged from 0.56 to 1.02 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.81, Medipal Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Distribution company?
The median Intrinsic Value: Projected FCF among Medical Distribution companies is 0.81, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current Intrinsic Value: Projected FCF of $27.04 is 3238.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median Intrinsic Value: Projected FCF is 0.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current Intrinsic Value: Projected FCF is $27.04, which is 3708% above median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Medipal Holdings (MEPDF) has a current Intrinsic Value: Projected FCF of $27.04. The stock's GF Value™ is $17.73, compared to a current price of $18.35 — trading 3.5% above its estimated fair value. The current Intrinsic Value: Projected FCF is $27.04, which is 3708% above median its 10-year median of 0.71 and 3238.3% above the Medical Distribution industry median of 0.81. Medipal Holdings' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Medipal Holdings (MEPDF), the current Intrinsic Value: Projected FCF is $27.04 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MEPDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $18.35 is trading 3.5% above its estimated GF Value™ of $17.73.
Key valuation signals for MEPDF:
Intrinsic Value: Projected FCF: $27.04 (3708% above median its 10-year median of 0.71)
GF Value™: $17.73 vs. price of $18.35 (3.5% above fair value)
Industry Position: 3238.3% above the Medical Distribution median (#27 of 75)
No single metric tells the full story. See the MEPDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
81GF Score
Get the complete analysis for MEPDF
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEPDF has been successfully added to your 
